carbapenems has been researched along with Communicable Diseases in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 15 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akova, M; Bassetti, M; Bitterman, R; Bonomo, RA; Carrara, E; Daikos, GL; de Waele, J; Gandra, S; Garnacho-Montero, J; Harbarth, S; Lindemann, PC; Mouton, JW; Paul, M; Pulcini, C; Retamar, P; Rodríguez-Baño, J; Seme, K; Tacconelli, E; Tängdén, T; Tumbarello, M; Yu, Y | 1 |
| Arnold, SLM; Baker, S; Ballell Pages, L; Castañeda, P; Cortés, A; Dayao, D; de Cozar, C; de Mercado, J; Fernández Álvaro, E; García-Perez, A; Ha Thanh, T; Martínez-Martínez, MS; Martinot, A; McCloskey, M; Pavlinac, P; Price, A; Shaheen, S; Singa, B; Tran Do Hoang, N; Tzipori, S; Urones, B; Voong Vinh, P; Walson, J; Willé, DR | 1 |
| Apisarnthanarak, A; Jantarathaneewat, K; Montakantikul, P; Nanthapisal, S; Rutjanawech, S; Weber, DJ | 1 |
| Aitken, SL; Bonomo, RA; Clancy, CJ; Mathers, AJ; Tamma, PD; van Duin, D | 3 |
| Aguado, JM; Fernández-Ruiz, M; Gutiérrez-Gutiérrez, B; Martínez-Martínez, L; Pascual, Á; Pérez-Nadales, E; Rodríguez-Baño, J; Torre-Cisneros, J | 1 |
| Bae, S; Chang, HH; Cheong, HS; Heo, ST; Hur, J; Hwang, S; Jung, DS; Kim, B; Kim, J; Kim, SW; Kim, Y; Kwon, KT; Lee, MS; Lee, S; Moon, C; Sohn, KM; Wi, YM; Yoon, YK | 1 |
| Fang, Q; Feng, Y; Hu, Y; McNally, A; Wang, C; Yang, Y; Zhao, F; Zong, Z | 1 |
| Cantón, R; Ruiz-Garbajosa, P | 1 |
| Duan, X; Li, S; Peng, Y; Rui, Y | 1 |
| Badia, X; Cantón, R; González, J; Huarte, R; Morata, L; Muñoz, R; Tort, M; Trillo-Mata, JL | 1 |
| Bryan, A; Bryson-Cahn, C; Chan, JD; Jain, R; Kim, HN; Krantz, EM; Lan, KF; Liu, C; Lynch, JB; Mani, NS; Pottinger, PS | 1 |
| Furuno, Y; Kanatani, N; Koga, H; Matono, T; Nakamura, K; Uchida, M; Umeda, Y; Yamashita, T | 1 |
| Bini, T; Cona, A; d'Arminio Monforte, A; Gazzola, L; Marchetti, GC; Viganò, O | 1 |
| Bian, X; Feng, M; Li, X; Liu, X; Song, S; Zhang, J; Zhang, X; Zheng, H | 1 |
| Ang, BS; Ling, LM; Lye, DC; Ng, TM; Phang, VY; Tan, MW; Tan, SH; Tay, HL; Teng, CB; Young, B | 1 |
| Al Zaibag, M; Aljohany, SM; Alothman, AF; Arabi, YM; Baharoon, S; Balkhy, HH; El-Metwally, A; El-Saed, A | 1 |
| Alp, E; Alves, J; Conway-Morris, A; Kalwaje Eshwara, V; Lagunes, L; Mer, M; Rello, J; Zhang, Z | 1 |
| Bodmann, KF | 1 |
| About, F; Berdougo, B; Brun-Buisson, C; De Pontfarcy, A; Delory, T; Emirian, A; Lesprit, P | 1 |
| Bi, J; Chen, X; Li, Y; Peng, Y; Shi, J; Yao, Z; Ye, X | 1 |
| Heist, BS; Higuchi, M; Honda, H; Horiuchi, M; Tagashira, Y; Tokuda, Y | 1 |
| Goodlet, KJ; Nailor, MD | 1 |
| Holbrook, KA; Lowy, FD | 1 |
5 review(s) available for carbapenems and Communicable Diseases
| Article | Year |
|---|---|
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Critical Care; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans | 2022 |
Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Communicable Diseases; Gram-Negative Bacteria; Humans; Organ Transplantation; Sepsis | 2022 |
Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.
Topics: Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Communicable Diseases; Humans; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Prevalence | 2023 |
Treatment guidelines for multidrug-resistant Gram-negative microorganisms.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Communicable Diseases; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests | 2023 |
Beta-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cephalosporins; Communicable Diseases; Humans; Penicillins | 1998 |
20 other study(ies) available for carbapenems and Communicable Diseases
| Article | Year |
|---|---|
The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Child; Communicable Diseases; Diarrhea; Drug Repositioning; Humans; Mice; Shigella; Swine | 2022 |
Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Guideline Adherence; Hospitals; Humans; Pharmacists; Thailand | 2022 |
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Child; Communicable Diseases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; United States | 2022 |
Use of Antibiotics Within the Last 14 Days of Life in Korean Patients: A Nationwide Study.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Humans; Republic of Korea; Retrospective Studies | 2023 |
Molecular characteristics of carbapenem-resistant Acinetobacter spp. from clinical infection samples and fecal survey samples in Southern China.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Colistin; Communicable Diseases; Drug Resistance, Bacterial; Feces; Genetic Variation; Genotype; Humans; Integrons; Microbial Sensitivity Tests; Polymerase Chain Reaction; Sequence Analysis, DNA | 2019 |
Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Spain | 2021 |
Postprescription Review With Threat of Infectious Disease Consultation and Sustained Reduction in Meropenem Use Over Four Years.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Humans; Meropenem; Referral and Consultation; Retrospective Studies | 2021 |
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aerug
Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Communicable Diseases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2021 |
Impact of an infectious disease physician-led carbapenem postprescription feedback on prescribing behavior in a Japanese tertiary hospital: A before-after study.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Controlled Before-After Studies; Feedback; Humans; Japan; Physicians; Tertiary Care Centers | 2021 |
Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Drug Resistance, Multiple, Bacterial; Female; Follow-Up Studies; Glycopeptides; Hospitals; Humans; Italy; Male; Middle Aged; Referral and Consultation; Retrospective Studies; Treatment Outcome | 2020 |
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aerug
Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Communicable Diseases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2021 |
Epidemiological and genomic characteristics of Acinetobacter baumannii from different infection sites using comparative genomics.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Communicable Diseases; Drug Resistance, Multiple, Bacterial; Genomics; Humans; Microbial Sensitivity Tests; Phylogeny | 2021 |
Clinical impact of non-antibiotic recommendations by a multi-disciplinary antimicrobial stewardship team.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Colistin; Communicable Diseases; Cost-Benefit Analysis; Drug Utilization; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Saudi Arabia; Tertiary Care Centers; Vancomycin; Young Adult | 2018 |
Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey.
Topics: Anti-Bacterial Agents; Carbapenems; Cohort Studies; Communicable Diseases; Critical Care; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Global Health; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Physicians | 2019 |
Oral Fosfomycin-Supplemental Information Necessary.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Fosfomycin; Humans | 2019 |
Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis.
Topics: Aged; Carbapenems; Communicable Diseases; Drug Utilization; Drug Utilization Review; Female; Humans; Male; Middle Aged; Prescriptions; Prospective Studies; Tertiary Care Centers; Vancomycin | 2013 |
Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care-associated infection control in the hospitals of Southern China: a case-control surveillance study.
Topics: Anti-Bacterial Agents; Carbapenems; Case-Control Studies; China; Communicable Diseases; Cross Infection; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Female; Hospitalization; Hospitals; Humans; Infection Control; Intubation, Intratracheal; Logistic Models; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors | 2014 |
Antimicrobial stewardship for carbapenem use at a Japanese tertiary care center: An interrupted time series analysis on the impact of infectious disease consultation, prospective audit, and feedback.
Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Drug Utilization; Feedback; Humans; Interrupted Time Series Analysis; Organizational Policy; Referral and Consultation; Tertiary Care Centers; Tokyo | 2016 |
Necessity of carbapenem use when prescribed per infectious diseases specialists.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Drug Prescriptions; Drug Utilization; Female; Health Services Research; Humans; Infectious Disease Medicine; Male; Middle Aged; Retrospective Studies; Specialization; Treatment Outcome; Young Adult | 2017 |